Abstract
Background
Barrett’s esophagus (BE) is recognized as a risk factor for esophageal adenocarcinoma.
An expert panel was organized in Italy with the aim of drafting a series of statements
on BE to guide diagnosis and management of patients with BE.
Methods
The working Group Coordinators worked on a literature search to identify key topics
regarding critical steps of the endoscopic approach to BE. Based on the search and
their expert opinion, a list of most meaningful questions was prepared and emailed
to all members who were asked to vote the questions. When the survey was completed
a consensus meeting was organized. According to the survey results, Group Coordinators
proposed a draft statement that was voted. By definition, the statement was formulated
when there was an agreement of ≥50% among participants.
Results
Twenty nine participants deliberated 18 questions. The agreement was reached for 16
questions for which a recommendation was formulated.
Conclusion
The generated statements highlight the Italian contribution to the European Position
Statement of the European Society of Gastrointestinal Endoscopy. The Italian statements
preserve peculiarities when dealing with the endoscopic management of BE and wishes
to be considered as a contribution for the care of BE patients even with a low risk
of progression to esophageal neoplasia.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.Endoscopy. 2017; 49: 191-198
- The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus.N. Eng. J. Med. 1985; 313: 857-859
- Etiology of Barrett’s metaplasia and esophageal adenocarcinoma.Cancer Epidemiol. Biomarkers Prev. 1997; 6: 369-377
- The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.J. Natl. Cancer Inst. 2005; 97: 142-146
- Oesophageal carcinoma.Lancet. 2013; 381: 400-412
- British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus.Gut. 2014; 63: 7-42
- American Gastroenterological Association medical position statement on the management of Barrett’s esophagus.Gastroenterology. 2011; 140: 1084-1091
- The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus.Gastrointest. Endosc. 2012; 76: 1087-1094
- Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.Gastroenterology. 2012; 143: 336-346
Koop H, Fuchs KH, Labenz J, Lynen Jansen P, Messmann H, Miehlke S, et al. S2k Leitlinie Gastroösophageale Refluxkrankkheit AWMF Register Nr. 021-013 unter Federführung Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Version 14. Juni 2014 Aktualisierung der Vorgängerversion von 2005 Weiterführende Dokumente: Leitlinienreport unter www.dgvs.de und www.awmf.de.
- Current surveillance policy for Barrett’s oesophagus in the Netherlands.Ned. Tijdschr. Geneeskd. 2007; 151: 1879-1884
- Dysplasia and early neoplasia in Barrett’s oesophagus.Diagn. Histopathol. 2012; 18: 411-420
- Diagnosis and treatment of Barrett’s oesophagus.Br. Med. Bull. 2013; 107: 117-132
- Diagnosis and treatment of Barrett’s oesophagus. A general survey.Acta Chir. Belg. 2001; 101: 53-58
- Barrett esophagus: history, definition and etiopathogeny.J. Med. Life. 2014; 7: 23-30
- Barrett’s esophagus. Diagnosis, follow-up and treatment.Dan. Med. J. 2012; 59: C4499
- The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria.Gastroenterology. 2006; 131: 1392-1399
- The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002.Gastrointest. Endosc. 2003; 58: S3-S43
- Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus.Gastrointest. Endosc. 2000; 51: 560-568
- Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial.Gut. 2013; 62: 15-21
- Advanced imaging technologies for the detection of dysplasia and early cancer in barrett esophagus.Clin. Endosc. 2014; 47: 47-54
- Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia.Am. J. Gastroenterol. 2000; 95: 3089-3096
- Comparison of high-resolution magnification narrow-band imaging and white-light endoscopy in the prediction of histology in Barrett’s oesophagus.Scand. J. Gastroenterol. 2009; 44: 85-92https://doi.org/10.1080/00365520802400818
- Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus.Gut. 2003; 52: 24-27
- Managing Barrett’s esophagus with radiofrequency ablation.Gastroenterol. Rep. (Oxf.). 2013; 1: 95-104
- Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review.Clin. Gastroenterol. Hepatol. 2013; 11 (e2): 1562-1570
- Update on narrow band imaging in disorders of the upper gastrointestinal tract.Dig. Endosc. 2014; 26: 144-153
- Diagnosis and management of Barrett’s esophagus for the endoscopist.Therap. Adv. Gastroenterol. 2010; 3: 227-238
- Endoscopic treatment of Barrett’s esophagus: from metaplasia to intramucosal carcinoma.World J. Gastroenterol. 2010; 16: 3780-3785
- Endoscopic submucosal dissection for superficial Barrett’s esophageal cancer in the Japanese state and perspective.Ann. Transl. Med. 2014; 2: 24
- High-resolution endoscopy and endoscopic ultrasound for evaluation of early neoplasia in Barrett’s esophagus.Surg. Endosc. 2010; 24: 1110-1116
- EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett’s esophagus.Gastrointest. Endosc. 2005; 62: 16-23
- EUS in the management of the patient with dysplasia in Barrett’s esophagus.J. Clin. Gastroenterol. 2005; 39: 263-267
- Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia.Clin. Gastroenterol. Hepatol. 2010; 8: 23-29
- Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett’s esophagus.Endoscopy. 2012; 44: 1105-1113
- Endoscopic therapy of esophageal premalignancy and early malignancy.J. Natl. Compr. Canc. Netw. 2011; 9: 890-899
- Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry.Gastroenterology. 2013; 145: 87-95
- Management strategies of Barrett’s esophagus.World J. Gastroenterol. 2012; 18: 6216-6225
- Endoscopic therapies for Barrett’s-associated dysplasia: a new paradigm for a new decade.Expert Rev. Gastroenterol. Hepatol. 2012; 6: 291-300
- Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.Cancer. 2007; 109: 668-674
- Risk factors in the development of esophageal adenocarcinoma.Am. J. Gastroenterol. 2013; 108: 200-207
- Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.Clin. Gastroenterol. Hepatol. 2013; 11: 1430-1436
- Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study.Am. J. Gastroenterol. 2011; 106: 1231-1238
- Familial trends of inheritance in gastro esophageal reflux disease, Barrett’s esophagus and Barrett’s adenocarcinoma: families.Dis. Esophagus. 2007; 20: 53-57
- High risk of malignancy in familial Barrett’s esophagus: presentation of one family.J. Clin. Gastroenterol. 2008; 42: 806-809
- A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.Eur. J. Cancer. 2008; 44: 465-471
- The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus.PLoS One. 2013; 8: e52192
- Risk factors for the development of esophageal adenocarcinoma in Barrett’s esophagus.Am. J. Gastroenterol. 2006; 101: 1421-1429
- Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study.Am. J. Gastroenterol. 2011; 106: 1447-1455
- Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus.Gastroenterology. 2012; 142: 233-240
- Familial aggregation of Barrett’s oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.Gut. 2002; 51: 323-328
- Risk factors for dysplasia in patients with Barrett’s esophagus (BE): results from a multicenter consortium.Dig. Dis. Sci. 2003; 48: 1537-1541
- Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma.Gut. 1992; 33: 1155-1158
- The relationship between smoking and severe dysplastic disease in patients with Barrett’s columnar-lined oesophagus.Eur. J. Cancer Prev. 2012; 21: 507-510
- Predictors of progression in Barrett’s esophagus: current knowledge and future directions.Am. J. Gastroenterol. 2010; 105: 1490-1502
- Radiofrequency ablation of Barrett’s esophagus: outcomes of 9 patients from a multicenter community practice registry.Endoscopy. 2010; 42: 272-278
National Institute for Health and Care Excellence. Endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia; 2014. http://www.nice.org.uk/guidance/IPG496/chapter/1-Recommendations.
- Radiofrequency ablation reduces the risk in Barrett’s oesophagus with dysplasia.Ugeskr. Laeger. 2014; 176: V06130409
- Ablative therapy for esophageal dysplasia and early malignancy: focus on RFA.BioMed Res. Int. 2014; 2014: 642063
- Radiofrequency ablation in the management of Barrett’s esophagus—preliminary own experience.Wideochir Inne Tech Maloinwazyjne. 2013; 8: 107-111
- Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia.Gastroenterology. 2011; 141: 460-468
- Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium.Gastroenterology. 2013; 145 (e1): 79-86
- Diagnosis and management of Barrett’s esophagus for the endoscopist.Therap. Adv. Gastroenterol. 2010; 3: 227-238
Article info
Publication history
Published online: September 01, 2017
Accepted:
August 15,
2017
Received in revised form:
August 14,
2017
Received:
May 12,
2017
Identification
Copyright
© 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
